top of page

Bruce Levine on UPenn's Center for Cellular Immunotherapies and his thoughts regarding FDA's recent CAR-T guidance

Dr. Levine highlights work being done at UPenn including a 3-day CAR with IL-18 and a dual CAR targeting GBM. Plus, his reaction to the secondary malignancy topic that has been in the news.



Join the BiotechTV mailing list

Thanks for subscribing!

Follow BiotechTV

  • Twitter
  • LinkedIn
  • Facebook
  • TikTok
  • Instagram

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

Allucent logo_tagline.png

Allucent Clinical Research Organization™ is on a mission to help bring new therapies to light by solving the distinct challenges of small and mid-sized biotech companies. We’re a global provider of comprehensive drug development solutions, including consulting, clinical operations, biometrics, and clinical pharmacology across a variety of therapeutic areas.

bottom of page